AU2002318342A2 - DNA molecules and recombinant DNA molecules for producing humanized monoclonal antibodies to S.Mutans - Google Patents

DNA molecules and recombinant DNA molecules for producing humanized monoclonal antibodies to S.Mutans Download PDF

Info

Publication number
AU2002318342A2
AU2002318342A2 AU2002318342A AU2002318342A AU2002318342A2 AU 2002318342 A2 AU2002318342 A2 AU 2002318342A2 AU 2002318342 A AU2002318342 A AU 2002318342A AU 2002318342 A AU2002318342 A AU 2002318342A AU 2002318342 A2 AU2002318342 A2 AU 2002318342A2
Authority
AU
Australia
Prior art keywords
seq
monoclonal antibody
antibody
chimeric monoclonal
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002318342A
Other languages
English (en)
Inventor
Maxwell H. Anderson
Li Chen
Sherie L. Morrison
Wenyuan Shi
Kham Trinh
Letitia Wims
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of AU2002318342A2 publication Critical patent/AU2002318342A2/en
Assigned to REGENTS OF THE UNIVERSITY OF CALIFORNIA reassignment REGENTS OF THE UNIVERSITY OF CALIFORNIA Request for Assignment Assignors: 3C Scientific Corporation, REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002318342A 2001-06-15 2002-06-11 DNA molecules and recombinant DNA molecules for producing humanized monoclonal antibodies to S.Mutans Abandoned AU2002318342A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/881,823 US20020068066A1 (en) 1999-08-20 2001-06-15 Method for the treatment and prevention of dental caries
US09/881,823 2001-06-15
PCT/US2002/018692 WO2002102975A2 (en) 2001-06-15 2002-06-11 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans

Publications (1)

Publication Number Publication Date
AU2002318342A2 true AU2002318342A2 (en) 2003-01-02

Family

ID=25379292

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002318342A Abandoned AU2002318342A2 (en) 2001-06-15 2002-06-11 DNA molecules and recombinant DNA molecules for producing humanized monoclonal antibodies to S.Mutans

Country Status (6)

Country Link
US (1) US20020068066A1 (enExample)
EP (1) EP1434799A4 (enExample)
JP (1) JP2004536824A (enExample)
AU (1) AU2002318342A2 (enExample)
CA (1) CA2448506A1 (enExample)
WO (1) WO2002102975A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US7875598B2 (en) * 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
CA2661634C (en) 2006-09-06 2017-03-28 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
CN101622271B (zh) 2007-01-16 2014-08-27 加利福尼亚大学董事会 抗微生物肽
AU2014203172B2 (en) * 2010-02-24 2016-03-10 Immunogen, Inc. Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CL2011003002A1 (es) * 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
SG10201912556VA (en) * 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
JP4731687B2 (ja) * 1998-08-21 2011-07-27 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア ストレプトコッカス・ミュータンスに特異的なモノクロナール抗体、およびその使用
AU2000270698A1 (en) * 2000-08-24 2002-03-04 Regents Of The Universtiy Of California Immunologic method for the prevention of dental caries

Also Published As

Publication number Publication date
EP1434799A2 (en) 2004-07-07
WO2002102975A3 (en) 2004-04-15
WO2002102975A2 (en) 2002-12-27
CA2448506A1 (en) 2002-12-27
US20020068066A1 (en) 2002-06-06
JP2004536824A (ja) 2004-12-09
EP1434799A4 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
Abiko Passive immunization against dental caries and periodontal disease: development of recombinant and human monoclonal antibodies
EP0994904B1 (de) Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch (clostridium difficile) toxine
AU731137B2 (en) Transgenic plants expressing assembled secretory antibodies
US20060258848A1 (en) Human antipneumococcal antibodies from non-human animals
US8986990B2 (en) Human antibodies against Pseudomonas aeruginosa LPS
US8491907B2 (en) Human anti-Pseudomonas-aeruginosa It-2 antibodies derived from transgenic xenomouse
US7005560B1 (en) Transgenic plants expressing assembled secretory antibodies
KR20120003017A (ko) 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도
CN102264762A (zh) 人抗pd-1、pd-l1和pd-l2的抗体及其应用
AU7287098A (en) Human monoclonal antibodies to epidermal growth factor receptor
CA2461989C (en) Method for treating multiple myeloma
US20020068066A1 (en) Method for the treatment and prevention of dental caries
US20030143234A1 (en) Anti-microbial targeting chimeric pharmaceutical
WO2002015931A1 (en) Immunologic method for the prevention of dental caries
US20210393711A1 (en) Bacteria expressing single chain antibodies against toll-like receptors
US7037722B1 (en) Transgenic plants expressing assembled secretory antibodies
US6995014B1 (en) Transgenic plants expressing assembled secretory antibodies
AU2007216785B2 (en) Human Antibodies Against Pseudomonas Aeruginosa LPS Derived from Transgenic Xenomouse
AU2002342740A1 (en) Human antipneumococcal antibodies from non-human animals
AU2001288866A1 (en) Human antibodies against pseudomonas aeruginosa LPS derived from transgenic xenomouse

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT( S) FILED 27 JAN 2004

PC1 Assignment before grant (sect. 113)

Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA

Free format text: FORMER APPLICANT(S): REGENTS OF THE UNIVERSITY OF CALIFORNIA; 3C SCIENTIFIC CORPORATION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted